About coagulation factor viii + von willebrand factor activity
Human coagulation factor VIII and von Willebrand factor
Used for
- Treatment and prevention of bleeding in haemophilia A.
- Treatment of bleeding and prevention during surgery in von Willebrand disease when other treatments are unsuitable.
Usual adult dose
Intravenous dosing is individualized by diagnosis, body weight, bleeding severity, and laboratory monitoring.
Usual dose in children
Used in children; intravenous dosing is individualized by diagnosis, body weight, bleeding severity, and laboratory monitoring.
Common side effects
- Headache, fever, or allergic reactions.
- Injection-site reactions.
- Development of factor VIII or von Willebrand factor inhibitors.
- Rare severe hypersensitivity, including anaphylaxis.
Important warnings
- Given by intravenous injection under specialist supervision.
- Factor VIII inhibitors can reduce treatment effectiveness.
- Allergic reactions may occur, especially in von Willebrand disease.
- Contains human plasma-derived proteins; residual infection risk is extremely low.
Pregnancy
Use when clinically needed; pregnancy-specific evidence is limited. Specialist assessment is important, particularly around delivery.
Breastfeeding
Use when clinically needed; information on passage into breast milk is limited.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.